Verdad Advisers’s Puma Biotechnology PBYI Stock Holding History

Verdad Advisers’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-55,542	Closed	-$330K	–	220
2025 Q4	$330K	Buy	+55,542	New	+$295K	0.38%	73

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Verdad Advisers's PBYI Position: Q1 2026 in Review

Verdad Advisers sold out of Puma Biotechnology (PBYI) in Q1 2026, closing a stake of 55,542 shares — an estimated $330K sold.

Verdad Advisers first reported a position in PBYI in Q4 2025 and held it in 1 quarter. The position peaked at $330K in Q4 2025. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

Verdad Advisers reported no remaining Puma Biotechnology position as of Q1 2026 after selling out during the quarter.
Verdad Advisers sold 55,542 Puma Biotechnology shares in Q1 2026, an estimated $330K.
Verdad Advisers first reported a position in Puma Biotechnology in Q4 2025 and held it in 1 quarter.
Verdad Advisers's Puma Biotechnology position peaked at $330K in Q4 2025.
157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.